Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma

Conclusions
Acquired resistance to sorafenib is driven by T-ICs with enrichment of progenitor markers and activation of IGF and FGF signalling. Inhibition of these pathways would benefit a subset of patients after sorafenib progression.

Source: Gut - February 14, 2017 Category: Gastroenterology Authors: Tovar, V., Cornella, H., Moeini, A., Vidal, S., Hoshida, Y., Sia, D., Peix, J., Cabellos, L., Alsinet, C., Torrecilla, S., Martinez-Quetglas, I., Lozano, J. J., Desbois-Mouthon, C., Sole, M., Domingo-Domenech, J., Villanueva, A., Llovet, J. M. Tags: Hepatic cancer Hepatology Source Type: research